Meet the wellness experts

Matthew Simms MBChB, DM, FRCS(Urol), Consultant Urologist

Men's Health Expert

Meet Mr Matthew Simms, Consultant Urologist and our Men’s Health Expert at Evergreen Life.


Matthew qualified in Sheffield in 1993 and after house positions, completed basic surgical training in Nottingham and Derby. He carried out research in bladder cancer before specialist training in urology in the East Midlands. After spending a year as a urology fellow at the Alfred Hospital in Melbourne, Australia, Matthew was appointed as a Consultant Urological Surgeon in Hull in 2006. At Evergreen Life, he helps develop content about men’s health.


  • MB ChB (Distinction in surgery) University of Sheffield 1993
  • FRCS (England) Royal College of Surgeons of England 1997
  • DM Nottingham University 2002
  • FRCS (Urol) Intercollegiate Surgical Board 2004

Additional training

  • Fellowship in Urological Oncology Alfred Hospital Melbourne Australia 2005
  • Mini-Fellowship in Bladder Reconstruction Urology and Nephrology Centre, Mansoura Egypt 2006
  • Male infertility and microsurgical training Weill Cornell Medical College, New York Presbyterian Hospital 2013



Matthew has had papers published in many journals throughout his career. Here are some of his most recent:

Devlin CM, Frame FM, Archer LK, Mann VM, Walker H, Simms MS, Berney DM, Collins AT, Maitland NJ. (2020). Over expression of Placental Growth Factor in Stromal Cells from Benign Prostatic Hyperplasia: Another Piece in the Puzzle? Eur Urol Open Sci. 2020 Sep 14;21:29-32. doi: 10.1016/j.euros.2020.08.003. PMID: 34337465; PMCID: PMC8317913.

Al-Mitwalli A, Kyriazis G, El-Taji O, Chandra E, Deborah W, Burns P, Fady Y, Simms M, Nicholas S. (2021). Selective transperineal prostate biopsy for fluoroquinolone-resistance patients reduces sepsis and cost. Curr Urol. 2021 Jun;15(2):115-118. doi: 10.1097/CU9.0000000000000013. Epub 2021 Apr 26. PMID: 34168531; PMCID: PMC8221012.

Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, Cross W, Logue J, Parulekar W, Payne H, Persad R, Pickering H, Saad F, Anderson J, Bahl A, Bottomley D, Brasso K, Chahal R, Cooke PW, Eddy B, Gibbs S, Goh C, Gujral S, Heath C, Henderson A, Jaganathan R, Jakobsen H, James ND, Kanaga Sundaram S, Lees K, Lester J, Lindberg H, Money-Kyrle J, Morris S, O'Sullivan J, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, Røder MA, Sayers I, Simms M, Wilson J, Zarkar A, Parmar MKB, Sydes MR. (2020). Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020 Oct 31;396(10260):1413-1421. doi: 10.1016/S0140-6736(20)31553-1. Epub 2020 Sep 28. PMID: 33002429.

Devlin CM, Simms MS, Maitland NJ. (2021). Benign prostatic hyperplasia - what do we know? BJU Int. 2021 Apr;127(4):389-399. doi: 10.1111/bju.15229. Epub 2020 Sep 24. PMID: 32893964.

Packer JR, Hirst AM, Droop AP, Adamson R, Simms MS, Mann VM, Frame FM, O'Connell D, Maitland NJ. (2020). Notch signalling is a potential resistance mechanism of progenitor cells within patient-derived prostate cultures following ROS-inducing treatments. FEBS Lett. 2020 Jan;594(2):209-226. doi: 10.1002/1873-3468.13589. Epub 2019 Sep 17. PMID: 31468514; PMCID: PMC7003772.

Interests & Specialisms

Matthew has a special interest in urological cancers, prostate disease and general urology. He has extensive experience in the management of urological cancers including minimally invasive robotic prostatectomy, bladder removal and bladder reconstruction. He also has an interest in men's health, male infertility and microsurgical vasectomy reversal.